- Conditions
- Hypertension
- Interventions
- Placebo, lorundrostat Dose 1, lorundrostat Dose 2
- Drug
- Lead sponsor
- Mineralys Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 285 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 104
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Mesa, Arizona + 88 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 97–120
of 4,513
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Ovarian Carcinoma
- Interventions
- Bilateral Salpingectomy, Bilateral Salpingectomy with Oophorectomy, Biospecimen Collection, Magnetic Resonance Imaging, Quality-of-Life Assessment, Questionnaire Administration, Transvaginal Ultrasound, Ultrasound Imaging
- Procedure · Other
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 35 Years to 50 Years · Female only
- Enrollment
- 1,956 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2047
- U.S. locations
- 564
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Goodyear, Arizona + 372 more
- Conditions
- Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia, T Acute Lymphoblastic Leukemia
- Interventions
- Allogeneic Hematopoietic Stem Cell Transplantation, Calaspargase Pegol, Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Dexrazoxane Hydrochloride, Doxorubicin, Etoposide, Filgrastim, Ifosfamide, Imatinib Mesylate, Laboratory Biomarker Analysis, Leucovorin Calcium, Levoleucovorin, Mercaptopurine, Methotrexate, Methylprednisolone, Pegaspargase, Prednisolone, Questionnaire Administration, Therapeutic Hydrocortisone, Thioguanine, Vincristine Sulfate
- Procedure · Drug · Biological + 1 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 352 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2034
- U.S. locations
- 184
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 145 more
- Conditions
- Tumors, Neoplasms
- Interventions
- TTI-237
- Drug
- Lead sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2005
- U.S. locations
- 3
- States / cities
- Lexington, Kentucky • Cleveland, Ohio • Nashville, Tennessee
- Conditions
- Chalazion
- Interventions
- SUN-131 1.5% TDS, Placebo TDS
- Drug
- Lead sponsor
- Senju USA, Inc.
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 263 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 65
- States / cities
- Chandler, Arizona • Prescott, Arizona • Sun City, Arizona + 56 more
- Conditions
- Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
- Interventions
- Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Electronic Health Record Review, Enfortumab Vedotin, Immunohistochemistry Staining Method, Magnetic Resonance Imaging, Multigated Acquisition Scan, Sacituzumab Govitecan, Trastuzumab Deruxtecan
- Procedure · Other · Drug + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 27
- States / cities
- Duarte, California • Encinitas, California • Irvine, California + 20 more
- Conditions
- Pancreatic Cancer
- Interventions
- fluorouracil, gemcitabine hydrochloride, radiation therapy
- Drug · Radiation
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 518 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1998
- U.S. locations
- 106
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 66 more
- Conditions
- Diabetes, Diabetes Mellitus, Type 2
- Interventions
- liraglutide, placebo
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 9,341 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 125
- States / cities
- Alabaster, Alabama • Birmingham, Alabama • Huntsville, Alabama + 106 more
- Conditions
- HIV Infections, Pneumococcal Infections
- Interventions
- 13-valent pneumococcal conjugate vaccine, Blood draw
- Biological · Procedure
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 331 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 15
- States / cities
- San Francisco, California • Aurora, Colorado • Washington D.C., District of Columbia + 8 more
- Conditions
- Lymphoma
- Interventions
- filgrastim, rituximab, carboplatin, etoposide, ifosfamide
- Biological · Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2006
- U.S. locations
- 85
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 55 more
- Conditions
- Head and Neck Cancer
- Interventions
- carboplatin, docetaxel
- Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2007
- U.S. locations
- 85
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 54 more
- Conditions
- Smoking Cessation
- Interventions
- Varenicline 1mg BID, Varenicline 0.5mg BID, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 12 Years to 19 Years
- Enrollment
- 312 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2018
- U.S. locations
- 56
- States / cities
- Ozark, Alabama • Goodyear, Arizona • Little Rock, Arkansas + 46 more
- Conditions
- Proliferative Diabetic Retinopathy (PDR)
- Interventions
- Vitrectomy, Endolaser, Faricimab, Panretinal Photocoagulation (PRP)
- Procedure · Device · Drug
- Lead sponsor
- Jaeb Center for Health Research
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 426 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 34
- States / cities
- Huntington Beach, California • Loma Linda, California • San Francisco, California + 30 more
- Conditions
- Idiopathic Pulmonary Fibrosis (IPF)
- Interventions
- Placebo for AZD8965, AZD8965 low dose, AZD8965 medium dose, AZD8965 high dose
- Other · Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 359 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 36
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Loma Linda, California + 30 more
- Conditions
- Colorectal Cancer, Pancreatic Cancer
- Interventions
- Irinotecan
- Drug
- Lead sponsor
- Reema A. Patel
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 178 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Lexington, Kentucky
- Conditions
- Multiple Myeloma
- Interventions
- Cilta-cel OOS Therapy
- Drug
- Lead sponsor
- Janssen Scientific Affairs, LLC
- Industry
- Eligibility
- 18 Years and older
- U.S. locations
- 137
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Goodyear, Arizona + 96 more
- Conditions
- Rheumatoid Arthritis (RA)
- Interventions
- Abatacept, Placebo for abatacept (0.9% Sodium Chloride Injection or Solution for Infusion), Upadacitinib, Placebo for upadacitinib
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 657 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 44
- States / cities
- Peoria, Arizona • Sun City, Arizona • Tucson, Arizona + 40 more
- Conditions
- PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Metastatic Pancreas Adenocarcinoma, Pancreatic Cancer, Pancreatic Cancer Metastatic, Pancreatic Adenocarcinoma Metastatic, Pancreatic Adenocarcinoma, Pancreatic Adenosquamous Carcinoma
- Interventions
- daraxonrasib
- Drug
- Lead sponsor
- Revolution Medicines, Inc.
- Industry
- Eligibility
- 18 Years and older
- U.S. locations
- 256
- States / cities
- Birmingham, Alabama • Daphne, Alabama • Dothan, Alabama + 198 more
- Conditions
- Non-Muscle Invasive Bladder Neoplasms
- Interventions
- Erdafitinib Intravesical Delivery System
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 235 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • Los Angeles, California • Lone Tree, Colorado + 22 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- albiglutide, albiglutide uptitration, placebo
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 309 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 247
- States / cities
- Alabaster, Alabama • Birmingham, Alabama • Dothan, Alabama + 205 more
- Conditions
- Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
- Interventions
- Alectinib, Brigatinib, Carboplatin, Ceritinib, Cisplatin, Crizotinib, Ensartinib, Lorlatinib, Pemetrexed
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 491
- States / cities
- Goodyear, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 341 more
- Conditions
- Dementia, Mild Cognitive Impairment
- Interventions
- Medication therapy management
- Behavioral
- Lead sponsor
- Daniela Moga
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Lexington, Kentucky
- Conditions
- Melanoma (Skin)
- Interventions
- vinorelbine
- Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- Not listed
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2004
- U.S. locations
- 86
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 56 more
- Conditions
- Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer
- Interventions
- Afatinib Dimaleate, Cetuximab, Laboratory Biomarker Analysis
- Drug · Biological · Other
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- Not listed
- Enrollment
- 174 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2026
- U.S. locations
- 638
- States / cities
- Fort Smith, Arkansas • Hot Springs, Arkansas • Jonesboro, Arkansas + 406 more